Onyvax
Company

Last deal

$14.9M
Local Amount - GBP 8M

Amount

Series C

Stage

08.05.2006

Date

3

all rounds

$29.8M

Total amount

General

About Company
Onyvax is a pharmaceutical company developing cancer therapies that use the immune system to target and destroy tumor cells.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1997

Operating Status

Closed

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.